Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG Appoints Ronald Scott As CEO To Succeed Anthony Man
Basilea Pharmaceutica AG announced that it has promoted Ronald Scott, previously Chief Operating Officer, to Chief Executive Officer (CEO) effective January 1, 2013 to succeed Anthony Man, who has decided for personal reasons to leave the Company as of December 31, 2012.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation For Treatment Of zygomycosis By U.S.
- Basilea Pharmaceutica AG And Astellas Pharma Inc Reports Positive Topline Phase 3 Results For Antifungal Isavuconazole
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation By U.S. FDA
- Basilea Pharmaceutica AG's Board Proposes Martin Nicklasson To Succeed Chairman Werner Henrich
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this